Overview
US and INJ rarely move in perfect sync. Today’s print ($1,882.43/$5.13) and 24h leaders (Injective) help frame which side currently carries relative strength.
Quick winners
Full comparison
| Metric | US | INJ |
|---|---|---|
| Price | $1,882.43 | $5.13 |
| Market Cap | $550.45M | $490.41M |
| FDV | — | — |
| Volume 24h | $9.26M | $2.59M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 184.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +3.64% | +5.97% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | US | INJ |
|---|---|---|
| 1H | — | — |
| 24H | -3.80% | +3.91% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | US | INJ |
|---|---|---|
| RSI | 49.02 | 49.29 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 67.35 | 0.29 |
| ADX | 21.33 | 12.19 |
| Support | 1,827.82 | 4.91 |
| Resistance | 1,960.30 | 5.47 |
| Trend | bearish | neutral |
| Momentum | 59.00 | — |
| Signal | neutral | neutral |
Automatic technical analysis
Automated technical notes for this pair highlight bearish conditions on US and neutral on INJ. Volatility differences can amplify short-term gaps.
Fundamentals
| Metric | US | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | — | 0.00 |
| Github activity | — | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
US
Injective
Pros and cons
Pros of US
- Higher ranking for US can translate into tighter spreads on major venues.
- US typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- Composite PEPS readings for US can surface clearer module agreement during trend phases.
Cons of US
- Regulatory or macro headlines can hit US harder simply because it is more visible.
- Large-cap status for US can mean slower percentage upside versus high-beta alternatives.
- Crowded positioning around US sometimes amplifies squeeze or flush risk.
- When dominance narratives fade, US can lag hotter rotation names.
Pros of Injective
- Diversifying versus US with Injective can change portfolio factor exposure.
- Active volume bursts on INJ sometimes precede sharper tactical moves.
- PEPS tracking for Injective still includes AI score and level context for monitoring.
- Narrative optionality around Injective can reprice quickly when catalysts appear.
Cons of Injective
- Weaker market-cap standing may leave Injective more exposed to liquidity droughts.
- Smaller book depth versus large caps can increase slippage for Injective.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
Across winners above, no single coin dominates every column. Prefer scenarios: trend continuation favors the side with aligned momentum; mean-reversion favors the side stretched on RSI.
AI summary
In about three hundred words of context: US (US) trades near $1,882.43 with a -3.80% day move, while Injective (INJ) is around $5.13 (+3.91%). Volume leadership currently sits with US, and market-cap leadership with US. Technical trend labels read bearish vs neutral, with RSI near 49.02/49.29. Bottom line: use this page as a structured checklist, then open each coin page and related PEPS tools before acting. Nothing here is financial advice.
FAQ
Which is better, US or Injective?
“Better” depends on horizon and risk. US leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, US or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both US and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. US currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.